Document Detail


Strategies for successful clinical management of schizophrenia with ziprasidone.
MedLine Citation:
PMID:  20658947     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: This review addresses practical clinical issues related to the use of ziprasidone in the treatment of schizophrenia using information from clinical trials, unpublished data, manufacturer's information, and input from an expert faculty of European psychiatrists with extensive experience of the use of ziprasidone, both in clinical trials and in everyday clinical practice.
AREAS COVERED IN THIS REVIEW: A Medline search of published data (1998 - 2010) was carried out, together with a review of unpublished data and manufacturer's information. In addition, expert opinion was sought from psychiatrists with extensive experience of ziprasidone in the treatment of schizophrenia in clinical settings across Europe.
WHAT THE READER WILL GAIN: This review has been undertaken to determine how the information from clinical trials can be optimally translated into 'real-life' practice and to establish how a decade of experience with ziprasidone in clinical practice can inform its optimal use to maximize effectiveness and minimize side effects.
TAKE HOME MESSAGE: Effective use of ziprasidone in everyday clinical practice usually requires rapid titration to doses in the range of 120 - 160 mg/day and administration with proper meals, thereby achieving the high levels of schizophrenia symptom control reported in clinical trials. Additional guidance is provided about effective management of side effects, and appropriate coadministration of benzodiazepines and other agents, to achieve desired outcomes.
Authors:
Andrea Fagiolini; Fernando Cañas; Bernd Gallhofer; Ilkka Larmo; Pedro Levy; José Manuel Montes; Georgios Papageorgiou; Mathias Zink; Alessandro Rossi
Related Documents :
20658947 - Strategies for successful clinical management of schizophrenia with ziprasidone.
22030767 - Meeting the challenge of practice quality improvement: a study of seven family medicine...
8315167 - Evaluating the performance of clinical dietitians.
21922027 - The practice of evidence-based medicine (ebm) in gastroenterology: discrepancies betwee...
7704647 - A systems approach to managing transformation.
19763207 - What puts a psychiatrist at risk for a malpractice lawsuit?
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  11     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-16     Completed Date:  2011-01-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  2199-220     Citation Subset:  IM    
Affiliation:
University of Siena School of Medicine, Department of Neuroscience, Viale Bracci 1, 53100 Siena, Italy. andreafagiolini@gmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antipsychotic Agents / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Comorbidity
Humans
Piperazines / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Randomized Controlled Trials as Topic
Risk Factors
Schizophrenia / drug therapy*
Thiazoles / administration & dosage,  adverse effects,  pharmacokinetics,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antipsychotic Agents; 0/Piperazines; 0/Thiazoles; 146939-27-7/ziprasidone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A high-throughput screen for alpha particle radiation protectants.
Next Document:  Development and description of GETT: a genetic testing evidence tracking tool.